IP Library Granted Patent US 7,803,593
Granted Patent B2
US 7,803,593 · App. 10/573,500 · Granted Sep 28, 2010

Acylglycerol acyltransferase-like protein MGAT-X1 and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,803,593
App. No.
10/573,500
Granted
Sep 28, 2010
Kind
B2
Abstract

The present invention is directed to a polynucleotide sequence of a novel acylglycerol acyltransferase-like protein MGAT-X1. The invention also provides the human MGAT-X1 associated with the dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases. The invention also provides assays for the identification of compounds useful for the modulation of dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases for treating of such diseases associated with expression of the MGAT-X1. The invention also features compounds which bind to and/or activate or inhibit the activity of MGAT-X1 as well as pharmaceutical compositions comprising such compounds.

Claims (16)

1. An isolated nucleic acid molecule selected from a group consisting of:

i) nucleic acid molecules encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2,

ii) nucleic acid molecules comprising the sequence of SEQ ID NO:1, and

iii) nucleic acid molecules consisting of the sequence of SEQ ID NO:1.

2. A vector comprising the nucleic acid molecule of claim 1 .

3. An isolated host cell containing a vector comprising the nucleic acid molecule of claim 1 .

4. A method of producing a polypeptide, comprising:

i) culturing a host cell comprising a vector which comprises the nucleic acid molecule of claim 3 under conditions suitable for the polypeptide to be expressed; and

ii) recovering the polypeptide from the culture medium.

5. A pharmaceutical composition comprising a nucleic acid molecule selected from the group consisting of:

i) nucleic acid molecules encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2, and

ii) nucleic acid molecules comprising the sequence of SEQ ID NO:1.

6. A pharmaceutical composition comprising a vector comprising a nucleic acid molecule selected from a group consisting of:

i) nucleic acid molecules encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2,

ii) nucleic acid molecules comprising the sequence of SEQ ID NO:1, and

iii) nucleic acid molecules having the sequence of SEQ ID NO:1.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 20, 2013
From: BAYER PHARMA AG
To: BAYER INTELLECTUAL PROPERTY GMBH
Reel/Frame 029839/0959 →
CHANGE OF NAME Recorded Oct 18, 2012
From: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
To: BAYER PHARMA AG
Reel/Frame 029150/0303 →
MERGER Recorded Feb 19, 2009
From: BAYER HEALTHCARE AG
To: BAYER SCHERING PHARMA AG
Reel/Frame 022277/0324 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2008
From: GOLZ, STEFAN; BRUGGEMEIER, ULF; WEINGARTNER, BERNHARD; GEERTS, ANDREAS
To: BAYER HEALTHCARE AG
Reel/Frame 021402/0692 →